Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin With and Without Lactulose in Recurrent Overt Hepatic Encephalopathy
NCT01842581Phase 4Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifaximin in hepatic encephalopathy (HE) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Number of Participants Reporting a First Breakthrough HE Episode at Day 170. Started Jan 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT01842581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842581.